

Rec'd PCT/PL

16 DEC 2002

10/070665

U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE  
STATEMENTDocket Number  
2653/56Application Number  
10/070,665Filing Date  
March 8, 2002Examiner  
To Be AssignedArt Unit  
To Be Assigned

Invention Title

POLYSIALIC ACID-KLH CONJUGATE VACCINE

Inventor(s)

LIVINGSTON, et al.

Commissioner  
for Patents  
Washington, D.C. 20231

I hereby certify that this correspondence is being hand-delivered to the United States Patent and Trademark Office, addressed to Commissioner for Patents, Washington, D.C. 20231.

Date: December 16, 2002


Reg. No. 38,413

Joseph A. Coppola

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicant hereby bring the following references to the attention of the Examiner. The references are listed on the attached modified PTO form 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.
2. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed, except as otherwise indicated on the modified PTO form 1449.

Dated: December 16, 2002

By:

  
Joseph A. Coppola (Reg. No. 38,413)KENYON & KENYON  
One Broadway  
New York, N.Y. 10004  
(212) 425-7200 (telephone)  
(212) 425-5288 (facsimile)

EL 828 17070448

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT  
PTO-1449**

ATTY. DOCKET NO.  
**2653/56**

SERIAL NO.  
**10/070,665**

APPLICANT(S) **LIVINGSTON, et al.**

FILING DATE  
**March 8, 2002**

GROUP  
**To be assigned**

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	INVENTORS NAME

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
				YES	NO

**OTHER DOCUMENTS**

EXAMINER INITIAL	AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
	Jain, Rakesh K., "Barriers to Drug Delivery in Solid Tumors", <i>Scientific American</i> , (July 1994) 271(1):58-65
	Burgess WH, et al., "Possible Dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue", <i>J Cell Biol</i> , (November 1990) 111(5 Pt 1):2129-38
	Curti, Brendan D., "Physical barriers to drug delivery in tumors" <i>Critical Reviews in Oncology/Hematology</i> , (1993) 14:29-39
	Hartwell, Leland H. et al., "Integrating Genetic Approaches into the Discovery of Anticancer Drugs" <i>Science</i> , (November 1997) 278:1064-1068
	Spitler, Lynn E., et al., "Cancer Vaccines: The Interferon Analogy", <i>Cancer Biotherapy</i> , (1995) 10(1):1-3
	Kseskmi, Y, et al., "Cancer "Vaccines": An Idea Whose Time Has Come?" <i>The Journal of NIH Research</i> , (January 1995) 7:46-49
	Gura Trisha, "Systems for Identifying New Drugs Are Often Faulty" <i>Science</i> , (November 1997) 278:1041-1042
	Boon, Thierry "Toward A Genetic Analysis of Tumor Rejection Antigens" <i>Advances in Cancer Research</i> , 58:177-211
	Helling, F., et al., "C <sub>12</sub> Vaccines for Melanoma: Superior Immunogenicity of Keyhole Limpet Hemocyanin Conjugate Vaccine" <i>Cancer Research</i> , (January 1994) 54:197-203
	Roth, Jurgen, et al., "Reexpression of poly(sialic acid) units of the neural cell adhesion molecule in Wilms tumor" <i>Proc. Natl. Acad. Sci.</i> , (May 1998) 85:2999-3003
	Jennings, H.J., et al., "Induction of Meningococcal Group B Polysaccharide-Specific IgG Antibodies in Mice By using an N-Propionylated B Polysaccharide-Tetanus Toxoid Conjugate Vaccine" <i>The Journal of Immunology</i> , (September 1986) 137(5):1708-1713
	Pon, R. A., "N-Propionylated Group B Meningococcal Polysaccharide Mimics a Unique Bactericidal Capsular Epitope in Group B Neisseria Meningitidis" <i>J. Exp. Med.</i> (June 1997) 185(11):1929-1938
	Livingston, P.O., "Approaches to Augmenting the Immunogenicity of Melanoma Gangliosides: From Whole Melanoma Cells to Ganglioside-KLH Conjugate Vaccines", <i>Immunological Reviews</i> (1995) 145:147-166

**EXAMINER**

**DATE CONSIDERED**

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.